Overview Dividends

(VTR) Ventas - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92276F1003

Senior Housing, Medical Buildings, Research Centers, Healthcare Facilities

VTR EPS (Earnings per Share)

EPS Growth (3Y CAGR): 44.58%
EPS Trend (3Y Correlation): 51.6%

VTR Revenue

Revenue Growth (3Y CAGR): 13.49%
Revenue Trend (3Y Correlation): 98.2%

Description: VTR Ventas October 14, 2025

Ventas, Inc. (NYSE: VTR) is a S&P 500-listed REIT focused on health-care real estate, operating roughly 1,400 properties across North America and the United Kingdom. Its core assets are more than 850 senior-housing communities, complemented by outpatient medical buildings, research centers, and other health-care facilities, positioning the company within the expanding “longevity economy.”

Key operational metrics show a FY 2023 occupancy rate of ~94% across senior-housing assets and a FY 2023 Funds-From-Operations (FFO) growth of 5% year-over-year, supporting a current dividend yield of about 5.5%. The portfolio’s performance is closely tied to macro drivers such as the U.S. aging demographic (projected to add ~10 million adults aged 65+ by 2030) and the prevailing interest-rate environment, which influences REIT cap rates and borrowing costs.

For investors seeking deeper quantitative insight, exploring ValueRay’s proprietary analytics on Ventas’ cash-flow sensitivity to interest-rate shifts can reveal hidden upside or downside scenarios worth further investigation.

VTR Stock Overview

Market Cap in USD	33,794m
Sub-Industry	Health Care REITs
IPO / Inception	1998-05-04

VTR Stock Ratings

Growth Rating	77.7%
Fundamental	64.9%
Dividend Rating	44.0%
Return 12m vs S&P 500	-2.27%
Analyst Rating	4.45 of 5

VTR Dividends

Dividend Yield 12m	2.55%
Yield on Cost 5y	5.47%
Annual Growth 5y	-4.27%
Payout Consistency	96.5%
Payout Ratio	3.8%

VTR Growth Ratios

Growth Correlation 3m	65.4%
Growth Correlation 12m	74%
Growth Correlation 5y	47.8%
CAGR 5y	26.84%
CAGR/Max DD 3y (Calmar Ratio)	1.17
CAGR/Mean DD 3y (Pain Ratio)	3.66
Sharpe Ratio 12m	1.45
Alpha	-3.05
Beta	0.909
Volatility	21.26%
Current Volume	4242.4k
Average Volume 20d	2024.2k
Stop Loss	71.9 (-3%)
Signal	0.97

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (56.8m TTM) > 0 and > 6% of Revenue (6% = 333.3m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 1.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -20.09% (prev 6.51%; Δ -26.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.06 (>3.0%) and CFO 1.55b > Net Income 56.8m (YES >=105%, WARN >=100%)

Net Debt (-188.6m) to EBITDA (1.89b) ratio: -0.10 <= 3.0 (WARN <= 3.5)

Current Ratio 0.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (456.4m) change vs 12m ago 8.80% (target <= -2.0% for YES)

Gross Margin 22.97% (prev 12.08%; Δ 10.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 21.25% (prev 18.94%; Δ 2.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 0.80 (EBITDA TTM 1.89b / Interest Expense TTM 752.5m) >= 6 (WARN >= 3)

Altman Z'' -1.55

(A) -0.04 = (Total Current Assets 188.6m - Total Current Liabilities 1.30b) / Total Assets 26.93b

(B) -0.27 = Retained Earnings (Balance) -7.37b / Total Assets 26.93b

(D) -0.52 = Book Value of Equity -7.29b / Total Liabilities 14.15b

Total Rating: -1.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 64.93

1. Piotroski 5.0pt = 0.0

2. FCF Yield 2.43% = 1.22

3. FCF Margin 20.74% = 5.19

4. Debt/Equity 1.11 = 1.91

5. Debt/Ebitda -0.10 = 2.50

6. ROIC - WACC (= -4.70)% = -5.87

7. RoE 0.49% = 0.04

8. Rev. Trend 98.25% = 7.37

9. EPS Trend 51.59% = 2.58

What is the price of VTR shares?

As of November 05, 2025, the stock is trading at USD 74.13 with a total of 4,242,400 shares traded.
Over the past week, the price has changed by +3.61%, over one month by +6.26%, over three months by +9.33% and over the past year by +18.63%.

Is Ventas a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Ventas is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 64.93 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VTR is around 77.55 USD . This means that VTR is currently overvalued and has a potential downside of 4.61%.

Is VTR a buy, sell or hold?

Ventas has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy VTR.

Strong Buy: 12
Buy: 5
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the VTR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	77.9	5%
Analysts Target Price	77.9	5%
ValueRay Target Price	85.6	15.4%

VTR Fundamental Data Overview November 01, 2025

Market Cap USD = 33.79b (33.79b USD * 1.0 USD.USD)
P/E Trailing = 172.9302
P/E Forward = 100.0
P/S = 6.4061
P/B = 2.7431
P/EG = 1.7374
Beta = 0.909
Revenue TTM = 5.56b USD
EBIT TTM = 601.3m USD
EBITDA TTM = 1.89b USD
Long Term Debt = 13.52b USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.40m USD (from shortTermDebt, last fiscal year)
Debt = 13.74b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -188.6m USD (from netDebt column, last quarter)
Enterprise Value = 47.35b USD (33.79b + Debt 13.74b - CCE 188.6m)
Interest Coverage Ratio = 0.80 (Ebit TTM 601.3m / Interest Expense TTM 752.5m)
FCF Yield = 2.43% (FCF TTM 1.15b / Enterprise Value 47.35b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 1.02% (Net Income TTM 56.8m / Revenue TTM 5.56b)
Gross Margin = 22.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 4.28b) / Revenue TTM)
Gross Margin QoQ = -29.31% (prev 41.80%)
Tobins Q-Ratio = 1.76 (Enterprise Value 47.35b / Total Assets 26.93b)
Interest Expense / Debt = 2.18% (Interest Expense 299.7m / Debt 13.74b)
Taxrate = -6.34% (negative due to tax credits) (6.34m / -100.1m)
NOPAT = 639.4m (EBIT 601.3m * (1 - -6.34%)) [negative tax rate / tax credits]
Current Ratio = 0.14 (Total Current Assets 188.6m / Total Current Liabilities 1.30b)
Debt / Equity = 1.11 (Debt 13.74b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = -0.10 (Net Debt -188.6m / EBITDA 1.89b)
Debt / FCF = -0.16 (Net Debt -188.6m / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.21% (Net Income 56.8m / Total Assets 26.93b)
RoE = 0.49% (Net Income TTM 56.8m / Total Stockholder Equity 11.53b)
RoCE = 2.40% (EBIT 601.3m / Capital Employed (Equity 11.53b + L.T.Debt 13.52b))
RoIC = 2.63% (NOPAT 639.4m / Invested Capital 24.35b)
WACC = 7.32% (E(33.79b)/V(47.54b) * Re(9.36%) + D(13.74b)/V(47.54b) * Rd(2.18%) * (1-Tc(-0.06)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.90%
[DCF Debug] Terminal Value 75.53% ; FCFE base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 45.99 (DCF Value 20.90b / Shares Outstanding 454.5m; 5y FCF grow 14.74% → 3.0% )
EPS Correlation: 51.59 | EPS CAGR: 44.58% | SUE: 0.15 | # QB: 0
Revenue Correlation: 98.25 | Revenue CAGR: 13.49% | SUE: 3.72 | # QB: 5

Additional Sources for VTR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle